<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36695401</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>26</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1538-7836</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of thrombosis and haemostasis : JTH</Title><ISOAbbreviation>J Thromb Haemost</ISOAbbreviation></Journal><ArticleTitle>Analysis of thrombogenicity under flow reveals new insights into the prothrombotic state of patients with post-COVID syndrome.</ArticleTitle><Pagination><StartPage>94</StartPage><EndPage>100</EndPage><MedlinePgn>94-100</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jtha.2022.10.013</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1538-7836(22)07182-3</ELocationID><Abstract><AbstractText Label="BACKGROUND">Post-COVID syndrome (PCS) affects millions of people worldwide, causing a multitude of symptoms and impairing quality of life months or even years after acute COVID-19. A prothrombotic state has been suggested; however, underlying mechanisms remain to be elucidated.</AbstractText><AbstractText Label="OBJECTIVES">To investigate thrombogenicity in PCS using a microfluidic assay, linking microthrombi, thrombin generation, and the von Willebrand factor (VWF):a Disintegrin and Metalloproteinase with a Thrombospondin Type 1 motif, member 13 (ADAMTS13) axis.</AbstractText><AbstractText Label="METHODS">Citrated blood was perfused through microfluidic channels coated with collagen or an antibody against the VWF A3 domain, and thrombogenicity was monitored in real time. Thrombin generation assays were performed and &#x3b1;(2)-antiplasmin, VWF, and ADAMTS13 activity levels were also measured.</AbstractText><AbstractText Label="RESULTS">We investigated thrombogenicity in a cohort of 21 patients with PCS with a median time following symptoms onset of 23 months using a dynamic microfluidic assay. Our data show a significant increase in platelet binding on both collagen and anti-VWF A3 in patients with PCS compared with that in controls, which positively correlated with VWF antigen (Ag) levels, the VWF(Ag):ADAMTS13 ratio (on anti-VWF A3), and inversely correlated with ADAMTS13 activity (on collagen). Thrombi forming on collagen presented different geometries in patients with PCS vs controls, with significantly increased thrombi area mainly attributable to thrombi length in the patient group. Thrombi length positively correlated with VWF(Ag):ADAMTS13 ratio and thrombin generation assay results, which were increased in 55.5% of patients. &#x3b1;(2)-Antiplasmin levels were normal in 89.5% of patients.</AbstractText><AbstractText Label="CONCLUSION">Together, these data present a dynamic assay to investigate the prothrombotic state in PCS, which may help unravel the mechanisms involved and/or establish new therapeutic strategies for this condition.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Constantinescu-Bercu</LastName><ForeName>Adela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Cardiovascular Science, Haemostasis Research Unit, University College London (UCL), London, United Kingdom. Electronic address: a.constantinescu-bercu@ucl.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kessler</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, University College London Hospitals NHS Foundation Trust, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Groot</LastName><ForeName>Rens</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Cardiovascular Science, Haemostasis Research Unit, University College London (UCL), London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dragunaite</LastName><ForeName>Bertina</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institute of Cardiovascular Science, Haemostasis Research Unit, University College London (UCL), London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heightman</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, University College London Hospitals NHS Foundation Trust, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hillman</LastName><ForeName>Toby</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, University College London Hospitals NHS Foundation Trust, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>Laura C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, University College London Hospitals NHS Foundation Trust, London, United Kingdom; National Pulmonary Hypertension Service, Royal Brompton Hospital, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brennan</LastName><ForeName>Ewan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, University College London Hospitals NHS Foundation Trust, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sivera</LastName><ForeName>Raphael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Cardiovascular Science, Haemostasis Research Unit, University College London (UCL), London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vanhoorelbeke</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Laboratory for Thrombosis Research, Katholieke Universiteit Leuven Campus Kulak Kortrijk, Kortrijk, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Deepak</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Special Coagulation, Health Services Laboratories, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scully</LastName><ForeName>Marie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Cardiovascular Science, Haemostasis Research Unit, University College London (UCL), London, United Kingdom; Department of Haematology, University College London Hospitals National Health Service Foundation Trust, London, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Thromb Haemost</MedlineTA><NlmUniqueID>101170508</NlmUniqueID><ISSNLinking>1538-7836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.21.5</RegistryNumber><NameOfSubstance UI="D013917">Thrombin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000933">Antifibrinolytic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.-</RegistryNumber><NameOfSubstance UI="D051722">ADAM Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014841">von Willebrand Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-34-5</RegistryNumber><NameOfSubstance UI="D003094">Collagen</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.87</RegistryNumber><NameOfSubstance UI="D000071120">ADAMTS13 Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013917" MajorTopicYN="N">Thrombin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000933" MajorTopicYN="Y">Antifibrinolytic Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051722" MajorTopicYN="N">ADAM Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014841" MajorTopicYN="N">von Willebrand Factor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013927" MajorTopicYN="Y">Thrombosis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003094" MajorTopicYN="N">Collagen</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071120" MajorTopicYN="N">ADAMTS13 Protein</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">microfluidics</Keyword><Keyword MajorTopicYN="N">post-COVID syndrome</Keyword><Keyword MajorTopicYN="N">thrombosis</Keyword><Keyword MajorTopicYN="N">von Willebrand factor</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>12</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36695401</ArticleId><ArticleId IdType="pmc">PMC9773628</ArticleId><ArticleId IdType="doi">10.1016/j.jtha.2022.10.013</ArticleId><ArticleId IdType="pii">S1538-7836(22)07182-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Carf&#xec; A., Bernabei R., Landi F. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324:603&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., Madhavan M.V., McGroder C., Stevens J.S., Cook J.R., Nordvig A.S., Shalev D., Sehrawat T.S., Ahluwalia N., Bikdeli B., Dietz D., Der-Nigoghossian C., Liyanage-Don N., Rosner G.F., Bernstein E.J., Mohan S., Beckley A.A., Seres D.S., et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Care Excellence (NICE) COVID-19 rapid guideline: managing the long-term effects of COVID-19. National Institute for Health and Care Excellence (NICE); London: 2020.</Citation><ArticleIdList><ArticleId IdType="pubmed">33555768</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for National Statistics  . 2022. ONS prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK.  https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/6may2022. Accessed May 6, 2022.</Citation></Reference><Reference><Citation>Davis H.E., Assaf G.S., McCorkell L., Wei H., Low R.J., Re'em Y., Redfield S., Austin J.P., Akrami A. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Jennings G., Monaghan A., Xue F., Mockler D., Romero-Ortu&#xf1;o R. A&#xa0;systematic review of persistent symptoms and residual abnormal functioning following acute COVID-19: ongoing symptomatic phase vs. post-COVID-19 syndrome. J&#xa0;Clin Med. 2021;10:5913.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8708187</ArticleId><ArticleId IdType="pubmed">34945213</ArticleId></ArticleIdList></Reference><Reference><Citation>Abou-Ismail M.Y., Diamond A., Kapoor S., Arafah Y., Nayak L. The hypercoagulable state in COVID-19: incidence, pathophysiology, and management. Thromb Res. 2020;194:101&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7305763</ArticleId><ArticleId IdType="pubmed">32788101</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackermann M., Verleden S.E., Kuehnel M., Haverich A., Welte T., Laenger F., Vanstapel A., Werlein C., Stark H., Tzankov A., Li W.W., Li V.W., Mentzer S.J., Jonigk D. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19. N&#xa0;Engl J Med. 2020;383:120&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7412750</ArticleId><ArticleId IdType="pubmed">32437596</ArticleId></ArticleIdList></Reference><Reference><Citation>von Meijenfeldt F.A., Havervall S., Adelmeijer J., Lundstr&#xf6;m A., Magnusson M., Mackman N., Thalin C., Lisman T. Sustained prothrombotic changes in COVID-19 patients 4 months after hospital discharge. Blood Adv. 2021;5:756&#x2013;759.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857699</ArticleId><ArticleId IdType="pubmed">33560386</ArticleId></ArticleIdList></Reference><Reference><Citation>Willems L.H., Nagy M., Ten Cate H., Spronk H.M.H., Groh L.A., Leentjens J., Janssen N.A.F., Netea M.G., Thijssen D.H.J., Hannink G., van Petersen A.S., Warl&#xe9; M.C. Sustained inflammation, coagulation activation and elevated endothelin-1 levels without macrovascular dysfunction at 3 months after COVID-19. Thromb Res. 2022;209:106&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8642246</ArticleId><ArticleId IdType="pubmed">34922160</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L., Fogarty H., Dyer A., Martin-Loeches I., Bannan C., Nadarajan P., Bergin C., O'Farrelly C., Conlon N., Bourke N.M., Ward S.E., Byrne M., Ryan K., O'Connell N., O'Sullivan J.M., Ni Cheallaigh C., O'Donnell J.S. Prolonged elevation of D-dimer levels in convalescent COVID-19 patients is independent of the acute phase response. J&#xa0;Thromb Haemost. 2021;19:1064&#x2013;1070.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8013297</ArticleId><ArticleId IdType="pubmed">33587810</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E., Vlok M., Venter C., Bezuidenhout J.A., Laubscher G.J., Steenkamp J., Kell D.B. Persistent clotting protein pathology in long&#xa0;COVID/post-acute sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol. 2021;20:172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8381139</ArticleId><ArticleId IdType="pubmed">34425843</ArticleId></ArticleIdList></Reference><Reference><Citation>Kell D.B., Laubscher G.J., Pretorius E. A&#xa0;central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications. BiochemJ. 2022;479:537&#x2013;559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8883497</ArticleId><ArticleId IdType="pubmed">35195253</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasannan N., Heightman M., Hillman T., Wall E., Bell R., Kessler A., Neave L., Doyle A.J., Devaraj A., Singh D., Dehbi H.-M., Scully M. Impaired exercise capacity in post-COVID syndrome: the role of VWF-ADAMTS13 axis. Blood Adv. 2022;6:4041&#x2013;4048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9098525</ArticleId><ArticleId IdType="pubmed">35543533</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancini I., Baronciani L., Artoni A., Colpani P., Biganzoli M., Cozzi G., Novembrino C., Boscolo Anzoletti M., De Zan V., Pagliari M.T., Gualtierotti R., Aliberti S., Panigada M., Grasselli G., Blasi F., Peyvandi F. The ADAMTS13-von Willebrand factor axis in COVID-19 patients. J&#xa0;Thromb Haemost. 2021;19:513&#x2013;521.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7753796</ArticleId><ArticleId IdType="pubmed">33230904</ArticleId></ArticleIdList></Reference><Reference><Citation>Kintigh J., Monagle P., Ignjatovic V. A&#xa0;review of commercially available thrombin generation assays. Res Pract Thromb Haemost. 2018;2:42&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6055498</ArticleId><ArticleId IdType="pubmed">30046705</ArticleId></ArticleIdList></Reference><Reference><Citation>Constantinescu-Bercu A., Grassi L., Frontini M., Salles C., II, Woollard K., Crawley J.T. Activated &#x3b1;(IIb)&#x3b2;(3) on platelets mediates flow-dependent NETosis via SLC44A2. eLife. 2020;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7253179</ArticleId><ArticleId IdType="pubmed">32314961</ArticleId></ArticleIdList></Reference><Reference><Citation>Alwan F., Vendramin C., Budde U., Liesner R., Taylor A., Thomas M., L&#xe4;mmle B., Scully M. Assessing thrombogenesis and treatment response in congenital thrombotic thrombocytopenic purpura. eJHaem. 2021;2:188&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9175835</ArticleId><ArticleId IdType="pubmed">35845267</ArticleId></ArticleIdList></Reference><Reference><Citation>Staelens S., Hadders M.A., Vauterin S., Platteau C., De Maeyer M., Vanhoorelbeke K., Huizinga E.G., Deckmyn H. Paratope determination of the antithrombotic antibody 82D6A3 based on the crystal structure of its complex with the von Willebrand factor A3-domain. J&#xa0;Biol Chem. 2006;281:2225&#x2013;2231.</Citation><ArticleIdList><ArticleId IdType="pubmed">16314412</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogarty H., Townsend L., Morrin H., Ahmad A., Comerford C., Karampini E., Englert H., Byrne M., Bergin C., O'Sullivan J.M., Martin-Loeches I., Nadarajan P., Bannan C., Mallon P.W., Curley G.F., Preston R.J.S., Rehill A.M., McGonagle D., Ni Cheallaigh C., Baker R.I., et al. Persistent endotheliopathy in the pathogenesis of long COVID syndrome. J&#xa0;Thromb Haemost. 2021;19:2546&#x2013;2553.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8420256</ArticleId><ArticleId IdType="pubmed">34375505</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Micco P., Russo V., Carannante N., Imparato M., Cardillo G., Lodigiani C. Prognostic value of fibrinogen among COVID-19 patients admitted to an emergency department: an Italian cohort study. J&#xa0;Clin Med. 2020;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7767519</ArticleId><ArticleId IdType="pubmed">33371524</ArticleId></ArticleIdList></Reference><Reference><Citation>Clemetson K.J., Clemetson J.M. Platelet collagen receptors. Thromb Haemost. 2001;86:189&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">11487007</ArticleId></ArticleIdList></Reference><Reference><Citation>Constantinescu-Bercu A., Wang Y.A., Woollard K.J., Mangin P., Vanhoorelbeke K., Crawley J.T., Salles C., II The GPIb&#x3b1; intracellular tail &#x2013; role in transducing VWF- and collagen/GPVI-mediated signaling. Haematologica. 2021;107:933&#x2013;946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8968903</ArticleId><ArticleId IdType="pubmed">34134470</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>